Milestone for Arana

By Dylan Bushell-Embling
Thursday, 02 October, 2008

Arana [ASX: ARA] has engineered an improved version of the VEGF-D antibody owned by Circadian Technologies [ASX: CIR] subsidiary Vegenics.

The antibody, designed to treat certain cancers, was modified into a humanised version using Arana's Superhumanisation technology.

It was then further refined using the company's EvoGene optimisation technology.

Conversion into humanised form will ensure that the risks of rejection of the treatment are minimised.

Circadian will shortly pay Arana milestone payments for the project, and Arana will be eligible to further milestone payments as the project advances through the various testing stages.

Related News

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...

Maternal cannabis use puts kids at risk of behavioural problems

Children exposed to their mother's cannabis use during pregnancy and after birth are three...

Over-the-counter pain relievers may improve concussion recovery

People who take over-the-counter pain relievers after a concussion may recover faster than those...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd